John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles School of Medicine, discusses immunogenicity in endometrial cancer.

Immunotherapy has had a big impact on patients with endometrial cancer. Glaspy states that patients with endometrial cancer are going to need to have access to the same sort of combinatorial trials as those that are available to patients with ovarian cancer.

Tumor mutational burden (TMB) analyses tend to be on the low end of the spectrum, as in ovarian cancer, says Glaspy. Therefore, the subset of patients with clear-cell disease would be a good place to focus because they have a higher TMB.

There are ongoing combinatorial immunotherapy trials for patients with endometrial cancer. There are trials that are open to patients with all tumor types, and those specifically enrolling patients with endometrial cancer, states Glaspy.

Videos

Dr. Glaspy on Immunotherapy in Endometrial Cancer

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center, director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles (UCLA) School of Medicine, discusses immunogenicity in ovarian cancer.

If tumor mutational burden is the problem with ovarian cancer, which it may be, says Glaspy, then physicians need to figure out how to introduce neoantigens into tumors to make them more immunogenic. There are a variety of possibilities, says Glaspy, including vaccines that can be directly injected into tumors that will cause them to express cytokines that render them more immunogenic. There is also a theory that radiating a tumor will cause it to break down and make it more likely to find a potentially viable antigen.

Epigenetics is another area of research that physicians hope will lead to gene expression that is more likely to be attacked by T cells. There are hundreds of other possibilities out there and sorting through them is going to be the challenge, Glaspy says.

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles (UCLA) School of Medicine, discusses immunogenicity in ovarian cancer.

John A. Glaspy, MD

Articles

Dr. Glaspy on Immunotherapy in Endometrial Cancer

Dr. Glaspy on Immunogenicity in Ovarian Cancer